A research network for the contemporary peptide field.
NeoPepp publishes stratified literature reviews on documented research compounds and supplies analytically characterized peptides for in vitro and laboratory research. The library is the foundation. The catalogue is downstream.
Documentation first.
NeoPepp does not operate as a retail vendor. The catalogue is short, deliberately. Every compound is supported by a stratified literature review covering peer-reviewed evidence, mechanism, regulatory status, and analytical standards. Researchers come for the documentation. The compound supports the work.
The research record is the asset. The compound is how the documentation gets used.
NeoPepp Research Desk
/OUR APPROACH/
01
Stratified Evidence
In vitro, animal, and human study data are presented at the tier they were generated. We do not collapse evidence categories or imply therapeutic outcomes.
02
Citation Provenance
Source attribution is documented per dossier. Where peer-reviewed literature concentrates in a single research lineage or commercial entity, this is disclosed openly.
03
Living Documentation
The research record does not stand still. New publications, replication studies, and regulatory developments update each compound's dossier as they appear.
Shape the future of the field.
NeoPepp partners with independent investigators, academic laboratories, and research institutions actively pushing the boundaries of peptide science. We supply the analytical-grade compounds; your work drives the next wave of clinical data.
/THE DEVELOPMENT PIPELINE/
Beyond the catalogue.
The public catalogue is deliberately narrow. We only publish what we have exhaustively documented. Internally, NeoPepp tracks the absolute frontier of peptide research—pipeline candidates, emerging clinical data, and independent replication studies. The published library is the proven foundation. The internal pipeline dictates what comes next.
Each quarter, we audit the global peptide pipeline against new clinical data, replication studies, and regulatory shifts. Compounds only graduate to the public catalogue when the literature is exhaustive and the analytical standards are locked. The rest stay in the R&D phase. We don't supply blind experiments—we supply the verified foundation for your research.
/THE NEOPEPP STANDARD/
A Deliberate Scope.
We prioritize depth over breadth. The public catalogue is intentionally narrow because the threshold for inclusion is absolute. A compound only goes live when its preclinical literature is fully stratified and its analytical testing protocol is locked.
Unfiltered Provenance.
Transparency is a research requirement. Where peer-reviewed literature concentrates in a single commercial entity, we flag it. Researchers receive the exact provenance of the evidence—not a sanitized, marketing-friendly summary.
Tiered Evidence.
We respect the data. In vitro, animal model, and human clinical findings are presented distinctly, exactly at the tier they were generated. We do not collapse evidence categories or project outcomes. The science speaks for itself.